News
Verismo Therapeutics, a clinical-stage CAR T company pioneering the KIR-CAR platform, today provided additional details on the Trials in Progress poster presentation at the upcoming 2025 American ...
Welcoming the full roster of attendees to the official start of summer school, Alexandra Boltasseva, the Ron and Dotty Garvin ...
Five-year follow-up data from the Phase 3 ARCHES trial shows XTANDI (enzalutamide) plus androgen deprivation therapy (ADT) reduces risk of death by 30% After a median follow-up of 61.4 months, ...
Bicycle Therapeutics plc , a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced the ...
Genmab A/S (Nasdaq: GMAB) announced today that it will present new research from its comprehensive development program evaluating its late-stage portfolio at the 2025 American Society of Clinical ...
3d
Zacks Small Cap Research on MSNFBLG: Poster Presentation Shows Potential for Fibroblast Therapy in Psoriasis…FBLG READ THE FULL FBLG RESEARCH REPORT Business Update Preclinical Psoriasis Data Presented at SID Annual Meeting On May 16, 2025, FibroBiologics, Inc. (NASDAQ:FBLG) announced a poster presentation ...
TEVIMBRA is a uniquely designed humanized immunoglobulin G4 (IgG4) anti-programmed cell death protein 1 (PD-1) monoclonal antibody with high affinity and binding specificity against PD-1. It is ...
Retroviral vectors that are both non-replicating and non-integrating represent a novel and attractive tool that has potential advantages for gene delivery therapy, immunotherapy, and vaccinology.
TOKYO, May 21, 2025 - (JCN Newswire) - Eisai Co., Ltd. announced today the presentation of clinical research across its oncology portfolio and pipeline during the 2025 American Society of Clinical ...
Nagpur: The National Service Scheme of Nagpur University and Jankalyankari Samiti Nagpur will be jointly organizing Vidarbha ...
Company's first development candidate in autoimmune and inflammatory disease (AIID) demonstrates potent blockade of IL-4, IL-13, and IL-33 signaling pathways critical in respiratory inflammationNovel ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results